AbCellera

116 articles about AbCellera

• AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing

  7/24/2023

  AbCellera (Nasdaq: ABCL) announced that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) has denied a rehearing request in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent).

• AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023

  7/6/2023

  AbCellera will announce its second quarter 2023 financial results on Thursday, August 3, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time the same day.

• AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

  5/29/2023

  AbCellera announced that executives from the Company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California on Tuesday, June 13, 2023, at 1:20 p.m. Pacific Time.

• AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients

  5/24/2023

  AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development.

• AbCellera Reports Q1 2023 Business Results

  5/4/2023

  AbCellera announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

• AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

  4/17/2023

  AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023.

• AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023

  4/11/2023

  AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).

• AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023

  4/6/2023

  AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

• AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

  3/22/2023

  AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).

• AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023

  3/14/2023

  AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19.

• AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023

  2/23/2023

  AbCellera (Nasdaq: ABCL) today announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

• AbCellera Reports Full Year 2022 Business Results

  2/21/2023

  AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2022.

• AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023

  2/1/2023

  AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).

• AbCellera to Report Full Year 2022 Financial Results on February 21, 2023

  1/24/2023

  AbCellera (Nasdaq: ABCL) will announce its full year 2022 financial results on Tuesday, February 21, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

• AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent

  1/19/2023

  AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent).

• AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023

  1/4/2023

  AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

• AbCellera and AbbVie Partner to Advance New Antibody Therapies

  12/15/2022

  AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV).

• 

  AbCellera Continues Partnership Frenzy with AbbVie Antibody Discovery Pact

  12/15/2022

  AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.

• AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases

  12/1/2022

  AbCellera and Rallybio Corporation announced that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.

• AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022

  11/10/2022

  AbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.